CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options with patients.
  • Appraise the similarities and differences among commercially available next-generation antiandrogen agents to personalize therapy selection for patients with prostate cancer.
  • Recognize the side effects associated with hormonal agents commonly employed in the management of prostate cancer, and evaluate recent data comparing the safety and tolerability of these therapies.
  • Explore available data with cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
  • Describe the rationale for testing patients with metastatic CRPC for BRCA1/2 or other mutations, and advise those found to harbor these genetic abnormalities about available data documenting the efficacy of PARP inhibition in specific settings.
  • Evaluate the recent FDA approvals of olaparib and rucaparib for patients with metastatic CRPC, and optimally incorporate these agents into clinical algorithms.
  • Counsel appropriately selected patients with prostate cancer about the availability of and participation in ongoing clinical trials.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Leonard G Gomella, MD
  The Bernard W Godwin Professor of Prostate Cancer
  Chairman, Department of Urology
  Senior Director, Clinical Affairs, Sidney Kimmel Cancer Center
  Enterprise VP for Urology, Jefferson Health System
  Thomas Jefferson University and Hospital
  Philadelphia, Pennsylvania
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP.
  
  Maha Hussain, MD, FACP, FASCO
  Genevieve Teuton Professor of Medicine
  Division of Hematology/Oncology
  Deputy Director
  Robert H Lurie Comprehensive Cancer Center
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pfizer Inc; Honoraria: Astellas, AstraZeneca Pharmaceuticals LP, Phillips Gilmore Oncology Communications Inc, Precisca, Sanofi Genzyme, UroToday; Patents, Royalties, Other Intellectual Property: Systems and Methods for Tissue Imaging, 3676, Licensed to IMBIO.
  
  A Oliver Sartor, MD
  Laborde Professor for Cancer Research
  Medical Director, Tulane Cancer Center
  Assistant Dean for Oncology
  Tulane Medical School
  New Orleans, Louisiana
  
  Consulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences.
  
  Neal D Shore, MD
  Director, CPI, Carolina Urologic Research Center
  Chief Medical Officer, Surgery/Urology, GenesisCare, US
  Medical Director, CUSP: Clinical Research Consortium
  Myrtle Beach, South Carolina
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CG Oncology, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exact Imaging, Exact Sciences Inc, FerGene, Foundation Medicine, GenesisCare, Invitae, Janssen Biotech Inc, MDxHealth, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Nymox Pharmaceutical Corporation, Pacific Edge, Pfizer Inc, Phosphorus, Propella Therapeutics Inc, Sanofi Genzyme, Sesen Bio, Tolmar, UroGen Pharma; Speakers Bureau: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Foundation Medicine, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Merck and Sanofi Genzyme.
  
  Release date: October 2021
  Expiration date: October 2022